Project Details
Description
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
| Status | Active |
|---|---|
| Effective start/end date | 6/25/25 → 6/29/29 |
Funding
- JANSSEN RESEARCH & DEVELOPMENT, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.